GILD
Price
$113.67
Change
-$0.73 (-0.64%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
141.95B
29 days until earnings call
GSK
Price
$40.20
Change
-$0.32 (-0.79%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
81.88B
35 days until earnings call
Interact to see
Advertisement

GILD vs GSK

Header iconGILD vs GSK Comparison
Open Charts GILD vs GSKBanner chart's image
Gilead Sciences
Price$113.67
Change-$0.73 (-0.64%)
Volume$118.09K
Capitalization141.95B
GSK
Price$40.20
Change-$0.32 (-0.79%)
Volume$64.39K
Capitalization81.88B
GILD vs GSK Comparison Chart in %
Loading...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GILD vs. GSK commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a StrongBuy and GSK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (GILD: $114.40 vs. GSK: $40.52)
Brand notoriety: GILD: Notable vs. GSK: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GILD: 113% vs. GSK: 84%
Market capitalization -- GILD: $141.95B vs. GSK: $81.88B
GILD [@Pharmaceuticals: Major] is valued at $141.95B. GSK’s [@Pharmaceuticals: Major] market capitalization is $81.88B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $669.64B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GILD’s FA Score shows that 3 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).

  • GILD’s FA Score: 3 green, 2 red.
  • GSK’s FA Score: 2 green, 3 red.
According to our system of comparison, GILD is a better buy in the long-term than GSK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GILD’s TA Score shows that 3 TA indicator(s) are bullish while GSK’s TA Score has 3 bullish TA indicator(s).

  • GILD’s TA Score: 3 bullish, 5 bearish.
  • GSK’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, GILD is a better buy in the short-term than GSK.

Price Growth

GILD (@Pharmaceuticals: Major) experienced а +3.19% price change this week, while GSK (@Pharmaceuticals: Major) price change was +1.17% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.08%. For the same industry, the average monthly price growth was +0.15%, and the average quarterly price growth was +13.52%.

Reported Earning Dates

GILD is expected to report earnings on Oct 23, 2025.

GSK is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.08% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GILD($142B) has a higher market cap than GSK($81.9B). GILD has higher P/E ratio than GSK: GILD (22.70) vs GSK (18.20). GILD YTD gains are higher at: 26.477 vs. GSK (23.875). GSK has less debt than GILD: GSK (17.4B) vs GILD (24.9B).
GILDGSKGILD / GSK
Capitalization142B81.9B173%
EBITDAN/A8.61B-
Gain YTD26.47723.875111%
P/E Ratio22.7018.20125%
RevenueN/A31.6B-
Total CashN/A3.62B-
Total Debt24.9B17.4B143%
FUNDAMENTALS RATINGS
GILD vs GSK: Fundamental Ratings
GILD
GSK
OUTLOOK RATING
1..100
7080
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
6
Undervalued
PROFIT vs RISK RATING
1..100
1262
SMR RATING
1..100
2940
PRICE GROWTH RATING
1..100
5052
P/E GROWTH RATING
1..100
10019
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (6) in the Pharmaceuticals Major industry is in the same range as GILD (15) in the Biotechnology industry. This means that GSK’s stock grew similarly to GILD’s over the last 12 months.

GILD's Profit vs Risk Rating (12) in the Biotechnology industry is somewhat better than the same rating for GSK (62) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than GSK’s over the last 12 months.

GILD's SMR Rating (29) in the Biotechnology industry is in the same range as GSK (40) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GSK’s over the last 12 months.

GILD's Price Growth Rating (50) in the Biotechnology industry is in the same range as GSK (52) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GSK’s over the last 12 months.

GSK's P/E Growth Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for GILD (100) in the Biotechnology industry. This means that GSK’s stock grew significantly faster than GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GILDGSK
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
61%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
59%
Bearish Trend 2 days ago
46%
Momentum
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
44%
MACD
ODDS (%)
Bearish Trend 2 days ago
36%
Bearish Trend 2 days ago
41%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
61%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
43%
Bullish Trend 2 days ago
53%
Advances
ODDS (%)
Bullish Trend 6 days ago
60%
Bullish Trend 3 days ago
59%
Declines
ODDS (%)
Bearish Trend 9 days ago
48%
Bearish Trend 9 days ago
52%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
42%
Bearish Trend 2 days ago
49%
Aroon
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
45%
View a ticker or compare two or three
Interact to see
Advertisement
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FDMT7.610.21
+2.84%
4D Molecular Therapeutics
GAP22.860.25
+1.11%
Gap Inc (The)
TECTP10.79N/A
N/A
Tectonic Financial
VERA25.96-0.15
-0.57%
Vera Therapeutics
SPCB12.54-0.24
-1.88%
SuperCom Ltd

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BMY. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+1.70%
BMY - GILD
48%
Loosely correlated
-0.16%
GSK - GILD
45%
Loosely correlated
-0.95%
BIIB - GILD
42%
Loosely correlated
-0.96%
NVS - GILD
42%
Loosely correlated
-0.44%
AMGN - GILD
41%
Loosely correlated
+0.28%
More

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with AZN. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
-0.95%
AZN - GSK
62%
Loosely correlated
-1.97%
PFE - GSK
57%
Loosely correlated
+0.37%
SNY - GSK
53%
Loosely correlated
-0.28%
JNJ - GSK
50%
Loosely correlated
+1.36%
MRK - GSK
46%
Loosely correlated
-0.55%
More